Literature DB >> 9836515

Differential protection in two transgenic lines of NOD/Lt mice hyperexpressing the autoantigen GAD65 in pancreatic beta-cells.

M Bridgett1, M Cetkovic-Cvrlje, R O'Rourke, Y Shi, S Narayanswami, J Lambert, V Ramiya, S Baekkeskov, E H Leiter.   

Abstract

Although expressed at very low levels in islets of NOD mice, GAD65 is a candidate islet autoantigen. Two transgenic lines of NOD/Lt mice expressing high levels of human GAD65 from a rat insulin promoter were generated. Transgenes were integrated on proximal chromosome 15 of the A line and on the Y chromosome of the Y line. Transgenic A-line mice were obligate hemizygotes, since homozygous expression resulted in developmental lethality. A twofold higher level of hGAD65 transcripts in A-line islets from young donors was associated with higher GAD protein and enzyme activity levels. Y-line males developed diabetes at a similar rate and incidence as standard NOD/Lt males. In contrast, A-line mice of both sexes exhibited a markedly lowered incidence of diabetes. Insulitis, present in both transgenic lines, developed more slowly in A-line mice and correlated with a reduction in the ratio of gamma-interferon to interleukin-10 transcripts. Splenic leukocytes from young A-line donors transferred diabetes into NOD-scid recipients at a retarded rate compared with those from nontransgenic donors. Further, nontransgenic NOD T-cells transferred diabetes more slowly in NOD-scid recipients that were congenic for A-line transgenes as compared with standard NOD-scid recipients. Primed T-cell responses and spontaneous humoral reactivity to GAD65 failed to distinguish transgenic from nontransgenic mice. Quantitative differences in expression level or insertional mutagenesis are possible mechanisms of protection in the A line.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9836515     DOI: 10.2337/diabetes.47.12.1848

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  13 in total

Review 1.  Immunotherapy of immune-mediated diabetes. Present and future.

Authors:  N Maclaren
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 2.  Animal models have little to teach us about type 1 diabetes: 2. In opposition to this proposal.

Authors:  E H Leiter; M von Herrath
Journal:  Diabetologia       Date:  2004-10-19       Impact factor: 10.122

Review 3.  Transgenic models of autoimmune disease.

Authors:  R J Boyton; D M Altmann
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

4.  GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes.

Authors:  Nepton Soltani; Hongmin Qiu; Mila Aleksic; Yelena Glinka; Fang Zhao; Rui Liu; Yiming Li; Nina Zhang; Rabindranath Chakrabarti; Tiffany Ng; Tianru Jin; Haibo Zhang; Wei-Yang Lu; Zhong-Ping Feng; Gerald J Prud'homme; Qinghua Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-27       Impact factor: 11.205

Review 5.  Nonobese diabetic mice and the genetics of diabetes susceptibility.

Authors:  Edward H Leiter
Journal:  Curr Diab Rep       Date:  2005-04       Impact factor: 4.810

6.  An evidence for surface expression of an immunogenic epitope of sarcoplasmic/endoplasmic reticulum calcium-ATPase2a on antigen-presenting cells from naive mice in the mediation of autoimmune myocarditis.

Authors:  Rajkumar Arumugam; Bharathi Yalaka; Chandirasegaran Massilamany; M S Shihabudeen Haider Ali; Ninaad Lasrado; Sabarirajan Jayaraja; Jean-Jack Riethoven; Xinghui Sun; Jay Reddy
Journal:  Immunobiology       Date:  2019-12-13       Impact factor: 3.144

Review 7.  Antigen-specific therapeutic approaches in Type 1 diabetes.

Authors:  Xavier Clemente-Casares; Sue Tsai; Carol Huang; Pere Santamaria
Journal:  Cold Spring Harb Perspect Med       Date:  2012-02       Impact factor: 6.915

8.  Prevention of type I diabetes transfer by glutamic acid decarboxylase 65 peptide 206-220-specific T cells.

Authors:  Seon-Kyeong Kim; Kristin V Tarbell; Maija Sanna; Mary Vadeboncoeur; Tibor Warganich; Mark Lee; Mark Davis; Hugh O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-20       Impact factor: 11.205

9.  T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event.

Authors:  Greig P Lennon; Maria Bettini; Amanda R Burton; Erica Vincent; Paula Y Arnold; Pere Santamaria; Dario A A Vignali
Journal:  Immunity       Date:  2009-10-08       Impact factor: 31.745

10.  Autoreactive human T-cell receptor initiates insulitis and impaired glucose tolerance in HLA DR4 transgenic mice.

Authors:  John A Gebe; Kellee A Unrath; Betty B Yue; Tom Miyake; Ben A Falk; Gerald T Nepom
Journal:  J Autoimmun       Date:  2007-10-18       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.